Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Go back to Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
(NASDAQ: GMAB) Delayed: 33.41 -0.7 (2.05%)
Previous Close $34.11    52 Week High
Open $33.60    52 Week Low
Day High $33.77    P/E N/A 
Day Low $33.20    EPS
Volume 6,348,461